Within this group, higher galectin-9 protein levels clearly predicted shorter treatment-free survival (Supplementary Fig. 11C) which was not the case in the IGHV-mutated group of CLL patients (Supplementary Fig. 11D). The gene discussed is LGALS9; the disease is B-cell chronic lymphocytic leukemia.